We investigated expression of the human ecotropic virus integration site-l (EVI1) gene in patients with leukemia and myelodysplastic syndrome (MDS) using the reverse transcriptase-polymerase chain reaction (RT-PCR) method. The EVll transcripts were detected in 5 (10.0%) of 50 patients with de novo acute myeloid leukemia (AML), including two AML patients with trilineage myelodysplasia, and in 8 (34.8%) of 23 patients with post-myelodysplastic syndrome AML (post-MDS AML). EVll expression was also detected in 6 (35.3%) of 17 MDS patients and three of six patients with chronic myeloid leukemia (CML) in myelomegakaryoblast crisis. No E V l l transcripts were detected in patients with acute lymphoid leukemia (n = 15) or CML in lymphoid blast crisis (n = 4). Chromosomal abnormalities at the 3q26 region, where the E V l l gene is located, were found in one HE GENETIC HETEROGENEITY of leukemia has been demonstrated at the molecular level.'-3 Gene activation at the transcriptional level is important in the ultimate development of cell-specific phenotypes in normal cellular differentiation and in leukemia:" Expression of GATA-I and the stem cell leukemia (SCL) gene is found in the normal development process of erythrocytic and megakaryocytic and GATA-1 may affect expression of the SCL gene. Thus, both factors may be essential to promote differentiation of these hematopoietic cell^.^"^ These transcription factors bind to GATA motif in the promoter region for target genes and control their expression.'S6 In leukemia cells, expression of transcription factors in a cell-specific manner has also been confirmed.6," Moreover, aberration of the transcription factor caused by a specific chromosomal translocation has been linked to l e u k e m o g e n e~i s .~~~~'~ Recently, we have shown that the expression patterns of GATA-l , GATA-2, and the SCL gene, lineage-specific transcription factors, may help to define the distinct phenotype of leukemia cells." This indicates that the pattern of expression of transcription factors in leukemia cells correlates with the differentiation level of hematopoietic cells.
The ecotropic virus integration site-l (EVI1) gene was identified as a gene associated with retrovirally induced myeloid leukemias in mice; it encodes a nuclear DNA-binding protein that contains two domains of Cys2His2 zinc finger~.''"~ The EVII gene shows a restricted pattern of expression and is not normally found in nonfractionated bone marrow or peripheral blood cells." The human EVII gene is transcriptionally activated in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS) by translocations or inversions involving the chromosomal band at 3q26, where the gene is located."-" In hematologic neoplasia with t(3;21) (q26;22), several genes at the 3q26 region, including the EVIl gene, fuse the AML-l gene resulting in novel transcripts.22.2' In AML with inv(3) (q21q26), breakpoints in a 400-kb region distal to the EVII locus were detected." These findings clearly indicate that ectopic expression of the EVIl gene patient with MDS and t w o patients with CML myelomegakaryoblast crisis who had EVll expression. Our results showed that EVll expression was frequent in patients with post-MDS AML and AML with trilineage myelodysplasia, regardless of the presence or absence of 3q26 abnormalities. EVll expression was accompanied by expression of GATA-1 and GATA-2, and often by stem cell leukemia (SCL) gene expression. In patients with post-MDS AML, E V l l expression was not always associated with a 3q26 abnormality, whereas EVll expression in CML myelomegakaryoblast crisis was often linked t o a 3q26 abnormality. Our results suggest that the leukemogenic role of EVll expression may differ between post-MDS AML and leukemia, with EVll expression associated with a 3q26 abnormality. is closely related to chromosomal aberrations at the 3q26 region.
Previous studies have shown that aberrant EVIl expression in a myeloid progenitor cell line may block granulocytic Furthermore, inappropriate expression of EVIl also blocks erythropoiesis by suppressing the transcription of a GATA-I target genedZ6 These findings allow us to speculate that EVI 1 expression may induce a differentiation block of, at least, granulocyte and erythrocyte lineages. Thus, the EVIl gene may play an important role in impaired hematopoiesis.
To understand the possible role of transcription factors in human leukemia and to obtain further insight into the expression of transcription factors in differentiating impairment of hematopoietic cells, we analyzed EVIl expression in various types of human leukemia, because a subset of leukemia has actually been shown to have differentiation block. We further investigated an association between EVIl expression and expression of other transcription factors. and 10 patients with CML in blast crisis (CML-BC). Seven patients with MDS were analyzed at both MDS and AML phases. One patient with MDS had t(3;4)(q26;q21), and two patients with CML-BC had inv(3)(q21q26) and t(3; 12;2O)(q26;q12;q13), respectively, in addition to the Philadelphia t r a n s l~c a t i o n .~~~~~ Diagnosis of de novo AML was performed using the FrenchAmerican-British (FAB) criteria." AML with trilineage myelodysplasia (AML-TMDS) was identified based on the previously described criteria?' diagnosis of AML-TMDS was made in two patients of 43 assessable de novo AML. Patients with post-MDS AML were identified based on the FAB criteria for acute leukemia; when greater than 30% of blasts were detected in the bone marrow or peripheral blood, transformation of MDS into the AML phase was considered to have occurred. All bone marrow and peripheral blood samples were acquired after informed consent was obtained from patients. We used two cell lines as controls: YS9;22, a myelomegakaryoblastic leukemia cell line with dic(3;3)(q26;~12)," and HAL-01, a B-precursor ALL cell line."' Bone marrow mononuclear cells from six healthy volunteers were also used as controls. Cytogenetic study was routinely performed after short-term (less than 48 hours) culture.** lmmunophenotyping and detection of platelet peroxidase activity. The presence of surface antigens associated with megakaryocytes/ platelets was determined by a modified indirect monoclonal antibody rosetting method using W 8 0 (CD41, GPIIbnIIa) and AN51 (CD42b, GPIb).28 For assessment of the involvement of a megakaryocytic lineage, a minimum of 15% blast cells positive for one or more lineage-specific monoclonal antibodies (MoAbs) was required as described?* To detect platelet peroxidase activity (PPO), ultrastructural cytochemical investigation was performed as described?'
Reverse transcription-polymerase chain reaction (RT-PCRJ protocol. For DNA synthesis, 1 pg of RNA was reacted with 50 ng of random hexamer and reverse transcriptase (Takara Shuzo, Kyoto, Japan). The cDNA product was amplified with 5 U of Taq polymerase and 50 ng of both 3"primer and 5"primer using a thermal cycler (Perkin Elmer, Nonvalk, CT). Oligonucleotide primers and probes used in this study are shown in Table  Cycle conditions for EVIl were 1 minute at 92"C, 1 minute at 6 2 T , and 2 minutes at 72°C through 30 cycles. The RT-PCR cycle condition to detect GATA-l, GATA-2, and SCL gene was reported previously." P r i m ers and a probe for 0-actin were used for the controls. Experiments were performed at least three times to confirm their reproducibility.
Detection of PCR products. A liquid hybridization of 10% of the PCR product was performed with a 5' end-laheled probe using a thermal cycler. Cycle conditions were 94°C for 30 seconds, a 10-minute ramp, and 42°C for 1 minute. Each hybridization sample was subjected to a run on 8% polyacrylamide gel. We attempted to assess the levels of EVII, GATA-I, GATA-2, and SCL expression semiquantitatively using densitometric analysis, although the RT-PCR technique is not sufficient to tell the amount of transcript precisely. As a control, we used the ratio of EVIl, GATA-I, GATA-2, and SCL expression to that of &actin in YS9;22 cells: then the ratio in each patient as compared with YS9:22 was calculated.
RESULTS

Frequency of EVII expression in human leukemiu cells.
None of the bone marrow cells obtained from healthy volunteers showed EVIl expression, confirming that EVIl gene is not expressed in nonfractionated normal bone marrow cells. Among 50 patients with de novo AML, only five patients (10.0%) had EVIl expression; however, none showed a detectable chromosomal change at 3q26. Two of the five AML patients showing EVI expression had AML-TMDS, and the other three patients had M1, M2, and M4 morphology (Table 2 ). In contrast, EVIl transcripts were detected in 8 (34.8%) of the 23 patients with post-MDS AML, including one patient with t(3;4)(q26;q21). Of 17 samples from MDS patients, six (35.3%) had EVIl expression; they consisted of three patients with refractory anemia (RA) and three (Table 2) .
To compare the EVIl expression pattern before and after leukemic transformation in MDS patients, we studied seven MDS patients subsequentially. Four of these patients did not show EVIl expression at the MDS and AML phases; however, the other three patients (42.9%) had EVIl expression both before and after leukemic transformation. No MDS patients who showed appearance or disappearance of EVI expression after leukemic transformation were noted, indicating that EVIl expression is not associated with disease progression of MDS. EVIl transcripts were also detected in three of six patients with CML myelomegakaryoblastic crisis, two of whom had chromosomal changes at 3q26, that is, inv(3)(q21q26) and t(3; 12;2O)(q26;q12;q13). In contrast, four patients with CML lymphoid blast crisis did not have EVIl transcripts under the RT-PCR condition. Similarly, none of the 15 patients with ALL had EVIl expression ( Ta-(Table 2) . Dysmegakaryopoiesis was evident in 9 of the 16 patients. Platelet-associated antigens were detected in two patients (cases 11 and 13) with post-MDS AML and three with CML in the myelomegakaryocyte blast crisis (cases 14, 15, and 16). In one patient (case 6), no platelet-associated antigens were detected in the MDS or AML phase, but PP0 activity was detected in the neoplastic cells.*' Clinically, a high platelet count was not observed in patients with EVIl expression, except for three patients with CML in myelomegakaryoblast crisis.
Chromosome abnormalities were detected in 11 of the 16 patients with EVII expression. The most frequently detectable abnormality was a change involving 3q26 (cases 6, 15, and 16) and monosomy 7 (cases 8, 12, and 13), followed by del(5q) (cases 10 and 12). Chromosome changes involving 1 lq23 were also noted in two patients (cases 4 and 8). One RAEB patient had t(3;4)(q26; q21), exhibiting megakaryocytic proliferation without thrombocyt~sis.~~ In contrast, two of three patients with CML in megakaryoblast crisis had 3q26 abnormalities.28 ble 2).
Association between EVIl expression and other erythroidCharacteristics of leukemia cells with EVIl expression.
megahryocyte-spec$ic transcription factors. We have We focused on 16 leukemia patients with EVIl expression shown that GATA-I, GATA-2, and SCL expression is re- Table 3 . BM cells, representative bone marrow cells obtained from a healthy volunteer; YS9;22, positive control: and HAL-01, neaative conlated to the cellular differentiation of leukemia cells: both GATA-I and SCL genes are commonly expressed in AML-M6 and "7, and also in leukemias bearing the plateletassociated antigens.I3 We also found that AML cells with GATA-I , but not SCL, expression may be derived from early myeloid progenitors.'' To determine an association between EVI 1 expression and other lineage-specific transcription factors. we also examined GATA-I , GATA-2, and SCL expression in the 16 patients with EVII expression (Table 3 and Fig I) .
GATA-I transcripts were detectable in all patients with EVII expression and in YS9:22 cells, but no GATA-I message was apparent in normal bone marrow cells, HAL-01 cells, and ALL cclls, indicating that the GATA-I message likely represents characteristics of leukemia cells rather than a contaminating erythroid component. Expression of GATA-2 was usually associated with GATA-I expression. except for one AML-M4 patient (case 4). although GATA-2 expression was also seen in normal bone marrow cells and was widely detected in leukemia cells with a nonlymphoid nature. as reported previously." Expression of SCL was not seen in cells obtained from normal bone marrow. SCL transcripts were detected in I 1 of the I6 patients with EVI I expression and most of them showed dysmegakaryopoiesis, the presence of platelet-associated antigens. or both. In the present study. we detected eight patients with SCL expression in 73 AML patients examined. and all of them had EVII transcripts. Patient 4 had SCL expression without any evidence of megakaryocytic or erythrocytic lineage involvement. Of the 60 AML patients without EVI 1 expression. we detected GATA-I expression in 3 1 (5 1.7%). GATA-2 in S3 (88.3%), and SCL in only one patient (1.7%). These findings indicate that EVII expression is always associated with GATA-I expression and is often associated with SCL expression: 67% of AML and 100% of CML-BC patients expressing EVI I had SCL transcripts (Tablc 3).
DISCUSSION
Acute leukemia may result from an impairment of cellular differentiation. A previous study showed that expression of EVll blocks myeloid differentiation in response to granulocyte colony-stimulating factor,'5 suggesting that EVI 1 expression may play a role in cellular differentiation in AML cells. Although the biologic characteristics of de novo AML have been extensively investigated. little is known about post-MDS AML. In de novo AML, the impairment of cellular differentiation is usually restricted to granulocytic or monocytic series: impaired erythropoiesis and megakaryopoiesis are uncommon. In contrast. the impairment of differentiation in multilineage hematopoiesis is a characteristic feature in post-MDS AML and AML-TMDS. In the current study, EVI I expression was frequently observed in patients with MDS, post-MDS AML, and AML-TMDS, regardless of detectable chromosomal changes at 3q26. Russell et alJ3 also reported that 14% of 23 MDS patients expressed the EVI 1 gene. We did not perform pulse-field gel electrophoresis using the EVII genomic probe. We performed Southern blot analysis. However, EcoRI-and RnrnHI-digested DNA from the 16 patients with EVll expression and YS9;22 cells did not show any rearrangements. Therefore, it is still unclear
expression in our patients without 3q26 abnormalities resulted from rearrangements around the EVIl locus. However, chromosomal abnormality at 3q26 is not frequently detected in MDS?4 Thus, it is natural to consider that EVIl expression in our patients may not be related to rearrangements around the EVIl gene. The high incidence of ectopic EVll expression might represent multilineage impaired hematopoiesis, because patients with EVIl expression were clustered in post-MDS and AML-TMDS; this finding was also noted in MDS patients. Moreover, in some MDS patients, EVIl expression was not related to disease progression, which allows the conclusion that EVIl expression without detectable 3q26 abnormalities represents impaired hematopoiesis.
EVIl expression was frequently associated with the expression of erythrocyte-and megakaryocyte-specific transcription factors, namely, GATA-1, GATA-2, and SCL. Kreider et alZ6 reported that impaired erythropoiesis may result from inappropriate expression of the EVIl gene, because EVIl expression may block erythropoiesis by repressing the transcription of a subset of GATA-1 target gene. Delwel et a135 reported that four of the seven zinc fingers of the EVII gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA sequence. More recently, it has been suggested that GATA-1 normally suppresses GATA-2 during erythropoiesis36 and that SCL regulates GATA-1 expression in erythrocytic differentiati~n.'~ The coordination of several transcription factors thus may play a key role in the development of normal hematopoiesis. In contrast, most leukemia patients with EVIl expression coexpressed the GATA-l and GATA-2 and often the SCL gene. Inappropriate expression of these transcription factors may represent the neoplastic nature of hematopoietic cells and may be linked to inappropriate differentiation of hematopoietic cells.
We have proposed that telomeres, the repeated sequence of the chromosome terminus, shorten as a result of genomic instability in MDS patients3* Genomic instability may induce not only deletion or mutation of certain gene(s) but also alteration of transcriptional activation of certain genes. In contrast, a high incidence of EVIl expression in patients with CML in myelomegakaryoblast crisis may reflect chromosomal instability that i s associated with disease progression rather than genomic instability. EVIl expression in CML is usually associated with 3q26 changes found as additional chromosomal abnormalities." Thus, EVIl expression may contribute to disease evolution in a subset of CML with 3q26 abnormalities, although it is still uncertain why EVIl expression is restricted to hematologic neoplasias expressing myelomegakaryoblastic phenotypes.
Proliferation and differentiation of hematopoietic cells is regulated by coordination of many genes. Our results show that the EVIl gene is preferentially expressed in leukemia with impaired hematopoiesis in two or more lineages. EVIl expression is also associated with GATA-l, GATA-2, or SCL expression, and inappropriate expression of these transcription factors may represent multilineage impairment of hematopoietic cells. Based on our results, we consider that the EVIl gene may be activated by at least two pathways.
One pathway is related to 3q26 abnormalities and expression of megakaryocytic phenotype, whereas the other is linked to multilineage impairment of hematopoietic cells, which usually do not show 3q26 abnormalities. For personal use only. on November 16, 2017. by guest www.bloodjournal.org From
